about
EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guideInternational and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus.Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy.Increase in Dickkopf-1 Serum Level in Recent Spondyloarthritis. Data from the DESIR Cohort.Increased Dickkopf-1 in Recent-onset Rheumatoid Arthritis is a New Biomarker of Structural Severity. Data from the ESPOIR CohortSafety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orencia in Rheumatoid Arthritis Registry.Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome[Beautification of data: Minimal fraud, incompetence or mixture of both].Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren's syndrome. Data at enrollment in the prospective ASSESS cohort.Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjögren's syndrome: results of the BELISS studySevere Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts.Plasma exchange for rheumatoid arthritis.Reporting of corticosteroid use in systemic disease trials: evidence from a systematic review of the potential impact on treatment effect.EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome.Outcome measures for primary Sjögren's syndrome.Outcome measures for primary Sjögren's syndrome: a comprehensive review.Reporting of results from network meta-analyses: methodological systematic review.Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations.Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force.New biological therapies in Sjögren's syndrome.Use of Biologics in Sjögren's Syndrome.Malignancy and the Risks of Biologic Therapies: Current Status.Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study.Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies.Brief Report: Monoclonal Gammopathy and Risk of Lymphoma and Multiple Myeloma in Patients With Primary Sjögren's Syndrome.Germline variation of TNFAIP3 in primary Sjögren's syndrome-associated lymphoma.Association of Anti-Porphyromonas gingivalis Antibody Titers With Nonsmoking Status in Early Rheumatoid Arthritis: Results From the Prospective French Cohort of Patients With Early Rheumatoid Arthritis.Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study.Role of the IL-12/IL-35 balance in Sjögren's syndrome.Treatment strategies and outcome of induction-refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial.Accurate detection of changes in disease activity in primary Sjögren's syndrome by the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index.Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjögren's syndrome.Genetic contribution of DKK-1 polymorphisms to RA structural severity and DKK-1 level of expression.
P50
Q26778262-C99F8A4B-F536-434E-BC44-677A8E638CEDQ30234696-4990B3D9-AC7F-46E9-A452-E377B555BB63Q30948155-2204B007-67AB-4082-A682-C0D56009AAE5Q30990351-5FA29B04-577E-47F9-982D-5CDC53CDDB3DQ31038073-E443A417-A595-477B-9CA2-807BB8016DC6Q31152756-56EE5AE9-A5E2-43AE-9D3B-8D2169EAE47DQ33372523-CA5C5EE0-3E5D-4197-82A7-08765AFEE16BQ34117422-FB9F2DA0-1F37-4D14-8CB7-DC181595DD83Q34355222-77B7BF58-9E67-418D-AC34-F3AAF0611E70Q34743817-F272900C-5730-411A-9DFD-27F186011614Q36027561-2C73E36A-42A1-47DA-A550-5A100C3011AFQ36070691-E65F7C33-6DA0-4019-826C-A9EB2F0AB8E2Q36175647-400A7B03-734F-4F3F-AC57-6436CA1690A9Q36821030-248858BD-50CF-4670-BE15-6E50C887F237Q37768733-A79625BF-F587-42B3-BC7A-CDACED456698Q37846349-DB49F035-48BC-4AB9-8A2B-B62888256034Q37988207-9C05AD46-877D-44D6-B445-A698899ECCA2Q38177429-641FD84B-7EE1-40CA-9776-79C329084105Q38195122-4921D409-1614-47C8-9202-768E50A9483FQ38675817-D7CB3504-DEB6-4D5E-95A3-B1B54F7D94C7Q38757421-A302B0F9-EB8C-4C60-8953-538EED01239EQ38815659-A6421786-ADB1-4DCF-9C55-0CA6C02E5E16Q38901446-C1C15F5D-EBFF-4F52-A43E-0CD94C520BA9Q39021242-D80E7011-B544-4DC7-AB76-B330142E7460Q39081726-C8C9057B-8140-4C42-8DAD-F9F1C03556EDQ39292745-CA5FE781-3011-400A-B0E6-7F4FA884132CQ39791068-B7173965-756B-486A-A0B1-4243910873FFQ41073760-C95D5840-7EB3-4D08-A0AB-18C7B993EEA6Q41419001-D1E144F8-7F21-4FBD-A904-F7AD54F439D3Q41425374-830A67A6-35AF-449A-9703-583A05C79F90Q41514433-56ABE15C-449A-496B-B7EC-2AEDD1A25977Q41936530-C969047D-BCB3-417D-94EE-CEB146768F90Q42965451-EF600F07-6210-4585-A937-253AC2D45E7FQ46070023-6993BE72-873F-4913-9FCA-95E6EF691CBEQ46223982-15364736-0966-48C2-963F-20A291A71EEAQ46519635-683FBAD0-D79F-49D9-AB71-1D0D04ED4E23
P50
name
Raphaèle Seror
@ast
Raphaèle Seror
@en
Raphaèle Seror
@nl
type
label
Raphaèle Seror
@ast
Raphaèle Seror
@en
Raphaèle Seror
@nl
prefLabel
Raphaèle Seror
@ast
Raphaèle Seror
@en
Raphaèle Seror
@nl
P214
P21
P213
0000 0001 3887 5214
P214
P31
P734
P735
P7859
viaf-193945490